9,27 Although the number of patients who had received prior adjuvant or neoadjuvant chemotherapy with trastuzumab was small, the progression-free survival benefit of pertuzumab plus trastuzumab ...

Patients were randomly assigned to neoadjuvant T-DM1+P or TCH+P every 3 weeks for six cycles. Patients who received T-DM1+P continued adjuvant T-DM1+P, and patients who received TCH+P received ...

Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome ...

9 Dual HER2 blockade with pertuzumab and trastuzumab is the standard of care as first-line therapy for patients with advanced HER2-positive disease. As part of a neoadjuvant regimen, pertuzumab ...

In the neoadjuvant phase, patients in the relevant study arms received pertuzumab plus trastuzumab plus docetaxel or trastuzumab plus docetaxel. In the adjuvant phase, patients in both study arms ...

NEW ORLEANS — Results from the I-SPY 2 trial show that a new presurgery (neoadjuvant) combination of trastuzumab emtansine (T-DM1; Kadcyla, Genentech, Inc) and pertuzumab (Perjeta, Genentech ...

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open ...

The term neoadjuvant means that a person typically ... A doctor may recommend both pertuzumab and trastuzumab if a person has a higher risk of recurrent breast cancer or metastases in the lymph ...

in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and ...